Highest-materiality recent filing
Globus Medical Q2 net sales $789.6M (+5.9%); non-GAAP EPS $1.34 (+55.8%), raises FY EPS guidance
Worldwide net sales $789.6M, +5.9% YoY; US +3.0%, International +18.0% as-reported.
Globus Medical Q1 2026: Net sales $759.9M (+27% YoY); raises FY non-GAAP EPS guidance to $4.70-$4.80
GAAP diluted EPS $0.90 (+66.6% YoY); non-GAAP diluted EPS $1.12 (+64.7% YoY).
Globus Medical Q4 revenue $826.4M (+25.7% YoY); EPS $1.03 GAAP / $1.28 non-GAAP
Q4 worldwide net sales $826.4M, up 25.7% YoY; base business ex-Nevro up 10.6%.
Globus Medical reports record Q4 sales $823M (+25% YoY); FY2026 guidance $3.18-3.22B
Preliminary Q4 2025 sales ~$823.2M, +25.2% YoY; full year sales ~$2.936B, +16.5% YoY.
Globus Medical Q3 revenue $769M (+23% YoY); raises FY2025 EPS guidance to $3.75-$3.85
Net sales $769.0M, +22.9% YoY; base business (ex-Nevro) $669.8M (+7.0%); Nevro contributed $99.3M.
Globus Medical Q2 net sales $745.3M (+18.4%); GAAP EPS $1.49, non-GAAP $0.86
Net sales $745.3M, up 18.4% YoY (17.6% constant currency); US Spine grew 5.7% as-reported.
Globus Medical CEO Scavilla resigns; Pfeil named CEO; preliminary Q2 sales $745.3M (+18% YoY)
Daniel Scavilla resigned as President and CEO effective July 18, 2025 to pursue another opportunity; no disagreement cited.
Globus Medical Q1 revenue down 1.4% to $598.1M; cuts non-GAAP EPS guidance to $3.00-$3.30
GAAP net income $75.5M; GAAP diluted EPS $0.54 vs ($0.05) a year ago.
Globus Medical completes acquisition of Nevro Corp. for $5.85/share cash
Completed acquisition of Nevro on April 3, 2025; each Nevro share received $5.85 in cash.
Globus Medical Q4 sales $657.3M (+6.6% YoY); guides 2025 with Nevro acquisition impact
Q4 net sales $657.3M (+6.6% as-reported, +6.9% constant currency); GAAP EPS $0.19, non-GAAP EPS $0.84.
Globus Medical to acquire Nevro for $5.85/sh in all-cash deal valued at ~$250M
All-cash transaction at $5.85/share; 27% premium to 90-day VWAP of $4.61.
Globus Medical prelim Q4 sales $657M (+6.6% YoY), FY24 $2.52B; guides FY25 rev $2.66-2.69B
Q4 2024 preliminary net sales ~$657M, up 6.6% as-reported vs Q4 2023; FY2024 ~$2.52B, up 60.6%.
Globus Medical Q3 net sales $625.7M (+63% YoY), raises FY24 revenue and EPS guidance
Worldwide net sales $625.7M, up 63.1% YoY, driven by NuVasive addition and higher spine/enabling tech sales.
Globus Medical receives FDA warning letter for ExcelsiusGPS complaint procedures
FDA warning letter cites non-conformities in complaint handling, trending, risk reconciliation, and MDR reporting for the ExcelsiusGPS robotic system.
Globus Medical Q2 revenue surges 115.9% to $629.7M; GAAP net income down 45%
Net sales $629.7M, up 115.9% as-reported; GAAP net income $31.8M, down 45% YoY.
Globus Medical shareholders approve amendment to 2021 Equity Incentive Plan
Plan amendment approved with 244,115,224 votes for, 78,950,353 against; effective June 5, 2024.
Globus Medical Q1 net sales $606.7M (+119% YoY); raises FY2024 guidance
Net sales $606.7M, up 119.3% YoY, driven by NuVasive addition and higher spine/enabling tech volumes.
Globus Medical Q4 net sales $616.5M (+124.6% YoY); non-GAAP EPS $0.60; reaffirms FY2024 guidance
Q4 net sales $616.5M, +124.6% as-reported (+123.8% constant currency); driven by NuVasive merger and organic growth.
Globus Medical reports record Q4 sales $615.5M (+124% YoY); FY2024 guidance $2.45-2.475B
Q4 2023 sales ~$615.5M, up 124.2% as-reported, including NuVasive merger impact.
Globus Medical files pro forma financials for NuVasive Merger; combined net income $6M for 9 months
Pro forma net income for nine months ended Sep 30, 2023: $6.0M ($0.04 diluted EPS) vs Globus standalone $107.8M.
Globus Medical Q3 revenue $383.6M (+51% YoY); raises FY revenue guidance to $1.55B
GAAP net income $1.0M, diluted EPS $0.01; non-GAAP diluted EPS $0.57 (+14.7% YoY).
Globus Medical enters $400M credit facility, authorizes $350M stock buyback
$400M unsecured credit agreement with U.S. Bank as agent; matures Sept 2028.
Globus Medical completes merger with NuVasive; expands board, converts notes
NuVasive shareholders received 0.75 Globus shares per share; NuVasive stock ceased trading Aug 31.
Globus Medical Q2 net sales $292M (+10.6% YoY); raises FY 2023 guidance to $1.125B
Net sales $291.6M, up 10.6% YoY; GAAP net income $57.7M (+5.7%).
Globus Medical Q1 net sales up 20% to $276.7M; non-GAAP EPS $0.53
Worldwide net sales $276.7M, up 20% YoY (21% constant currency); GAAP net income $49.1M.
Globus Medical, NuVasive get FTC second request for merger; Q3 2023 close expected
FTC issued Second Request on May 3, 2023, extending HSR waiting period for the merger.
Globus Medical shareholders approve share issuance for NuVasive merger; 99.92% vote in favor
99.92% of votes cast approved share issuance; 99.66% of Class A and 100% of Class B voted for.
Globus Medical Q4 net sales $274.5M (+9.8% YoY); full year exceeds $1B; guides 2023 sales $1.1B
Q4 GAAP diluted EPS $0.49, non-GAAP diluted EPS $0.59; net income $50.1M (+231% YoY).
Globus Medical to acquire NuVasive in $3.1B all-stock merger; 0.75 exchange ratio
Exchange ratio: 0.75 GMED shares per NUVA share; implied price $57.72; equity value $3.1B.
Globus Medical to acquire NuVasive in all-stock merger; each NuVasive share gets 0.75 GMED share
Each NuVasive share converted into 0.75 Globus Medical Class A common shares; no cash consideration except fractional shares.
Globus Medical Q3 net sales $254.1M (+10.6% YoY); lowers FY22 non-GAAP EPS guidance to $2.03
Q3 net sales $254.1M, up 10.6% as-reported and 12.6% constant currency; GAAP net income $47.4M, +0.5% YoY.
Globus Medical Q2 net sales $263.6M (+5% YoY); GAAP EPS $0.53, non-GAAP $0.56; Enabling Tech +41.7%
Net sales $263.6M, +5.0% as-reported and +6.5% constant currency vs Q2 2021.
Globus Medical Q1 2022 net sales $230.5M, up 1.4% YoY; GAAP EPS $0.37, non-GAAP $0.42
Net sales $230.5M, up 1.4% YoY (1.9% constant currency); U.S. spine sales recovered in March.
Globus Medical names Dan Scavilla as CEO replacing Demski; prelim Q1 sales $230.5M +1.4% YoY
David Demski resigned as CEO effective April 21, 2022; not due to any disagreement; will assist transition through June 30.
Globus Medical expands share repurchase program by $200M; total capacity over $295M
Board authorized additional $200M for share repurchases, supplementing ~$95.3M remaining from prior program.
Globus Medical Q4 sales $250M (+7.1% YoY); FY21 sales $958.1M (+21.4%); guides FY22 sales $1.025B
Q4 GAAP diluted EPS $0.14, non-GAAP $0.49; GAAP net income $15.1M down 71.5% due to IPR&D acquisition
Worldwide net sales $229.7M (+6.3% YoY); US sales +8.8%, International -7.2%.
Globus Medical Q2 revenue $251M (+68.6% YoY); raises FY2021 guidance to $950M sales, $1.89-2.00 EPS
Q2 worldwide net sales of $251.0M, up 68.6% YoY; GAAP net income $41.5M (16.6% of sales), up 299.4% YoY.
On February 5, 2024, Globus Medical, Inc. (the “Company”) issued a news release announcing the promotion of Keith Pfeil to Chief Operating Officer and Chief Financial Officer, effective as of February 1, 2024.
on September 1, 2023, the board of directors of Globus (the “Globus Board”) elected and designated Leslie V. Norwalk, John A. DeFord, and Daniel J. Wolterman (collectively, the “New Directors”), who were previously members of the board of directors of NuVasive, to serve on the Globus Board effective immediately after the consummation of the Merger.
on September 1, 2023, the board of directors of Globus (the “Globus Board”) elected and designated Leslie V. Norwalk, John A. DeFord, and Daniel J. Wolterman (collectively, the “New Directors”), who were previously members of the board of directors of NuVasive, to serve on the Globus Board effective immediately after the consummation of the Merger.
on September 1, 2023, the board of directors of Globus (the “Globus Board”) elected and designated Leslie V. Norwalk, John A. DeFord, and Daniel J. Wolterman (collectively, the “New Directors”), who were previously members of the board of directors of NuVasive, to serve on the Globus Board effective immediately after the consummation of the Merger.
On April 20, 2022, Mr. Demski also notified the Board of his resignation as President and Chief Executive Officer of the Company, effective April 21, 2022.
On April 21, 2022, the Board of Directors of the Company approved the appointment of Daniel T. Scavilla as President and Chief Executive Officer, effective April 21, 2022.
On April 21, 2022, the Board appointed Mr. Scavilla to serve as a member of the Board and as a member of the Nominating and Corporate Governance Committee with a term expiring at the Company’s annual meeting in 2023 to fill the vacancy created by the resignation of Mr. Demski.
On April 20, 2022, David M. Demski notified the Chairman of the Board of Directors (the “Board”) of the Company of his resignation from the Board effective April 20, 2022.
Max materiality 0.90 · Median 0.75 · Most common event earnings